Navigation Links
BiondVax Announces Third Quarter 2016 Financial Results and Update

NESS ZIONA, Israel, Nov. 28, 2016 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, today announced its third quarter 2016 financial results for the quarter ended September 30, 2016 and provided a business update.

Third Quarter 2016 Financial Summary

Results are in New Israel Shekels (NIS) and convenience translation to US$ is provided using the exchange rate of 3.758 (NIS/US$) as at September 30, 2016.

  • Third quarter operating expenses were NIS 3.47m ($923,000) compared with NIS 2.21m for the third quarter of 2015;
  • Third quarter R&D expenses amounted to NIS 2.42 ($644,000) compared with NIS 1.24m for the third quarter of 2015;
  • Cash, cash equivalents and short and long-term marketable securities at the end of the quarter were NIS 29.67m ($7.97m) compared with NIS 37.53m as of December 31, 2015;  
  •  Recent Corporate Update

  • The European UNISEC consortium sponsored Phase 2b processed the final participant in September. Study samples are currently being analyzed by the consortium and are expected to be finalized and released in the coming months.
  • Preparations for the United States NIH Phase 2 clinical trial is ongoing and progressing according to plan.
  • Professor Shai Ashkenazi, an experienced clinician-researcher who has guided multiple vaccines through clinical and regulatory approval phases to market was appointed to BiondVax's Scientific Advisory Board.   
  • Dr. Ron Babecoff, CEO of BiondVax commented: "I am pleased that we are working according to plans both in the US and Europe."

    About BiondVax BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit

    Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results of the contemplated  Phase 2 & 3 trials, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the impact of the global economic environment on the Company customer target base, the adequacy of available cash resource and the ability to raise capital when needed. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.

    ** Tables to Follow **

     BALANCE SHEETSConvenience
    (Note 2)December 31, September 30,September 30,2015201520162016AuditedUnauditedUnauditedN I SU.S. dollars(In thousands except share and per share data)CURRENT ASSETS:Cash and cash equivalents33,47036,29415,0914,016Short term bank deposit-57810,5102,797Marketable securities2,0162,0162,017537Other receivables1,4421,59472719336,92840,48228,3457,543LONG-TERM ASSETS:    Marketable securities2,0482,0472,050545Property, plant and equipment2,0442,1911,592424Other long term assets28724370984,3794,2624,0121,06741,30744,74432,3578,610CURRENT LIABILITIES:Trade payables931571477127Other payables7687584661241,6991,329943251LONG-TERM LIABILITIES:Options5,9946,8633,528938Severance pay liability, net696774206,0636,9303,602958SHAREHOLDERS' EQUITY (DEFICIT):Ordinary shares of NIS 0.0000001 par value: Authorized: 391,000,000 shares as of September
    30, 2016, 2015 (unaudited) and December 31,
    2015; Issued and Outstanding: 135,097,367,
    shares as of September 30, 2016, 2015
    (unaudited) and December 31, 2015.*) -*) -*) -*) -Share premium110,679110,352111,69729,722Options2,5362,5362,536675 Other comprehensive income121282Accumulated deficit(79,682)(76,415)(86,429)(22,998)33,54536,48527,8127,40141,30744,74432,3578,610*)            Represents an amount lower than NIS 1.

    translation(Note 2)Year endedDecember 31,Three months endedSeptember 30, Nine months endedSeptember 30, Nine months endedSeptember30, 201520152016201520162016AuditedUnauditedUnauditedN I SU.S. dollars(In thousands, except per share data)Operating expenses:Research and development, net of participations7,9061,2472,4215,0325,9621,586Marketing, general and administrative3,3979661,0492,2162,819750Total operating expenses11,3032,2133,4707,2488,7812,336Operating loss11,3032,2133,4707,2488,7812,336Financial income1,1181,540106515916Financial expense(24)(5)(291)(20)(491)(131)Financial  income (expenses) due to revaluations of options108121,395(315)2,466656Total finance income , net1,1042,3471,1143162,034541Net loss (income)                                           10,199(134)2,3566,9326,7471,795Other comprehensive loss (income):Items to be reclassified to profit or loss in
    subsequent periods:Gain (loss) from available-for-sale financial
    assets(5)(2)1(5)(4)(1)Total comprehensive loss (income)10,204(132)2,3556,9376,7511,796Basic and diluted net loss per share (NIS)0.10(0.00) average number of shares outstanding used to compute basic and diluted loss per share105,522,642135,097,367135,097,36795,519,426135,097,367135,097,367

    Contact Details Joshua Phillipson
    Business Development Manager
    +972 8 930 2529
    Kenny Green
    Investor Relations
    +1 646 201 9246  

    To view the original version on PR Newswire, visit:

    SOURCE Biondvax Pharmaceuticals Ltd
    Copyright©2016 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. BiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option
    2. BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
    3. Independent Results Show that BiondVaxs Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
    4. BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
    5. BiondVax to Present on October 8 at the Aegis Growth Conference
    6. Biondvaxs Universal Flu Vaccine Receives Additional US Patent
    7. BiondVax Receives Additional Grant Approval
    8. BiondVax CEO to Present at Roth Conference on Wednesday, March 16
    9. BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference
    10. Pharmagen Announces First Quarter 2013 Results
    11. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
    Post Your Comments:
    (Date:9/18/2019)... ... 2019 , ... Lake Minnetonka Orthodontics, with locations in Minnetonka, ... Hybrid-Responsive™ website: . , The staff of Lake Minnetonka Orthodontics ... with the practice more easily online. Improvements include increased usability, online scheduling, and ...
    (Date:9/18/2019)... , ... September 18, 2019 , ... The interns of ... all attended the Youth Consultation Services Foundation (YCS) in Hackensack , where NJ ... spent time with the children and threw them a pizza party and handed out ...
    (Date:9/17/2019)... AUCKLAND, New Zealand (PRWEB) , ... September 17, 2019 , ... ... Mention in in Fast Company’s 2019 Innovation by Design Awards Students category. , It ... Lab at the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A ...
    Breaking Medicine Technology:
    (Date:9/17/2019)... BROOKFIELD, Wis. (PRWEB) , ... September 17, 2019 , ... Milwaukee-area dealership Hall Cars has ... have been affected by cancer. The event, entitled “Drive Out Cancer,” entails that for every ... This Time Tomorrow Foundation. As the event lasts for 50 days, it has also been ...
    (Date:9/17/2019)... , ... September 17, 2019 , ... ... for Europe and the 21st Century Cures Act in the US, Nocimed has ... and pain management. Using images from existing MRI equipment to perform MR ...
    (Date:9/17/2019)... ... September 17, 2019 , ... Drs. Charles Felts and ... teeth in Chattanooga, TN for customized full mouth dental implants with TeethXpress® ... one day, providing a permanent tooth replacement solution for patients who struggle with ...
    (Date:9/17/2019)... ... ... Lubin Austermuehle, P.C. will be one of the sponsors of GRIN2B ... Found Kitchen and Social House in Evanston on Monday, October 7 from 6 p.m. ... rare condition that results from changes to the GRIN2B gene. The GRIN2B gene is ...
    (Date:9/17/2019)... ... September 17, 2019 , ... Genomenon ... with the goal of providing resources to assist researchers and encourage pharmaceutical companies ... disease causing abnormal iron deposits in the brain. , BPAN Warriors is ...
    Breaking Medicine News(10 mins):